PriceTargets.com logo

Organigram - OGI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: C$3.00
  • Forecasted Upside: 46.34%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
C$2.05 As of 02/2/2026 11:35 AM ET
▲ +0.02 (0.99%)

This chart shows the closing price for OGI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Organigram Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OGI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OGI

Analyst Price Target is C$3.00
▲ +46.34% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Organigram in the last 3 months. The average price target is C$3.00, with a high forecast of C$3.00 and a low forecast of C$3.00. The average price target represents a 46.34% upside from the last price of C$2.05.

This chart shows the closing price for OGI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Organigram. This rating has held steady since February 2025, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/10/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/8/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/6/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/7/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/5/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/2/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2026

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/27/2026Canaccord Genuity GroupSet TargetBuyC$3.00
12/17/2024ATB CapitalLower TargetC$5.25 ➝ C$3.50
12/9/2024Canaccord Genuity GroupLower TargetSpeculative BuyC$3.60 ➝ C$3.15
8/14/2024Canaccord Genuity GroupBoost TargetSpeculative BuyC$3.25 ➝ C$3.60
5/17/2024Jefferies Financial GroupLower TargetC$4.40 ➝ C$4.35
5/15/2024Canaccord Genuity GroupLower TargetSpeculative BuyC$3.75 ➝ C$3.25
4/3/2024ATB CapitalSet TargetOutperformC$5.25
2/27/2024Jefferies Financial GroupLower TargetBuyC$4.95 ➝ C$4.40
2/14/2024Alliance Global PartnersBoost TargetNeutralC$2.00 ➝ C$2.70
12/20/2023ATB CapitalBoost TargetOutperformC$5.50 ➝ C$6.50
12/20/2023Alliance Global PartnersLower TargetC$2.25 ➝ C$2.00
12/20/2023Canaccord Genuity GroupLower TargetC$4.00 ➝ C$3.75
7/18/2023Haywood SecuritiesLower TargetC$5.00 ➝ C$3.00
7/17/2023Stifel NicolausBoost TargetC$1.25 ➝ C$4.00
7/17/2023Alliance Global PartnersBoost TargetC$1.00 ➝ C$2.25
7/17/2023ATB CapitalLower TargetC$9.00 ➝ C$6.50
7/17/2023Canaccord Genuity GroupLower TargetC$9.00 ➝ C$4.00
4/21/2023Jefferies Financial GroupLower TargetC$1.80 ➝ C$1.50
4/13/2023ATB CapitalLower TargetC$2.50 ➝ C$2.25
4/13/2023Canaccord Genuity GroupLower TargetC$3.25 ➝ C$2.25
4/13/2023Haywood SecuritiesLower TargetC$1.60 ➝ C$1.25
4/13/2023Stifel NicolausLower TargetC$1.50 ➝ C$1.25
2/28/2023Jefferies Financial GroupLower TargetC$2.00 ➝ C$1.80
1/13/2023Alliance Global PartnersLower TargetC$1.50 ➝ C$1.30
1/13/2023Stifel NicolausUpgradeHold ➝ Buy
12/23/2022Jefferies Financial GroupLower TargetC$2.60 ➝ C$2.00
8/31/2022Eight CapitalLower TargetC$2.60 ➝ C$1.70
7/19/2022Jefferies Financial GroupLower TargetMarket PerformC$3.34 ➝ C$2.60
7/15/2022Haywood SecuritiesLower TargetHoldC$2.50 ➝ C$1.90
7/15/2022Stifel NicolausLower TargetC$2.25 ➝ C$1.50
4/14/2022Raymond James FinancialSet TargetOverweightC$3.00
4/13/2022Jefferies Financial GroupLower TargetC$3.44 ➝ C$3.34
4/13/2022ATB CapitalUpgradeSector Perform ➝ OutperformC$3.00
4/12/2022Atb Cap MarketsUpgradeSector Perform ➝ Outperform
3/15/2022Raymond James FinancialLower TargetOutperformC$5.00 ➝ C$3.00
1/12/2022ATB CapitalBoost TargetSector PerformC$2.65 ➝ C$3.00
1/12/2022Canaccord Genuity GroupUpgradeHold ➝ Speculative BuyC$3.00 ➝ C$3.25
1/10/2022Raymond James FinancialReiterated RatingOutperformC$5.00
1/7/2022Alliance Global PartnersLower TargetNeutral ➝ UnderperformC$4.00 ➝ C$2.25
12/22/2021Raymond James FinancialReiterated RatingOutperformC$5.00
11/30/2021Jefferies Financial GroupLower TargetMarket PerformC$3.83 ➝ C$3.49
11/25/2021Raymond James FinancialSet TargetOutperformC$5.00
11/24/2021Alliance Global PartnersLower TargetUnderperformC$3.75 ➝ C$3.00
11/24/2021ATB CapitalLower TargetC$4.25 ➝ C$2.65
11/19/2021Raymond James FinancialSet TargetOutperformC$5.00
9/24/2021CIBCReiterated RatingNeutral
9/23/2021CIBCLower TargetNAC$4.00 ➝ C$3.50
9/15/2021Raymond James FinancialReiterated RatingOutperformC$5.00
9/3/2021Jefferies Financial GroupBoost TargetC$3.57 ➝ C$3.83
8/5/2021Raymond James FinancialReiterated RatingOutperformC$5.00
7/23/2021Atb Cap MarketsReiterated RatingSector Perform
7/14/2021Raymond James FinancialReiterated RatingOutperformC$5.00
7/14/2021ATB CapitalBoost TargetNAC$3.75 ➝ C$4.25
7/14/2021CIBCBoost TargetC$3.75 ➝ C$4.00
7/9/2021CIBCReiterated RatingNeutralC$3.75
7/8/2021Raymond James FinancialReiterated RatingOutperformC$5.00
6/11/2021CIBCBoost TargetUnderperformC$3.25 ➝ C$3.75
5/11/2021CIBCUpgradeUnderperform ➝ Neutral
5/11/2021Royal Bank Of CanadaUpgradeNeutral
5/4/2021Raymond James FinancialReiterated RatingOutperformC$5.00
4/22/2021Jefferies Financial GroupBoost TargetC$3.48 ➝ C$3.57
4/15/2021Alliance Global PartnersLower TargetUnderpeformC$4.00 ➝ C$3.75
4/14/2021Haywood SecuritiesLower TargetUnderperformC$4.75 ➝ C$3.50
4/14/2021ATB CapitalLower TargetUnderperformC$4.20 ➝ C$3.75
4/14/2021Alliance Global PartnersBoost TargetUnderperformC$3.75 ➝ C$4.00
4/14/2021CIBCDowngradeNeutral ➝ UnderperformC$5.00 ➝ C$3.25
4/13/2021Raymond James FinancialLower TargetOutperformC$6.00 ➝ C$5.00
4/7/2021Raymond James FinancialReiterated RatingOutperformC$6.00
4/6/2021CIBCReiterated RatingNeutralC$5.00
3/12/2021Raymond James FinancialBoost TargetOUTPERFORMC$3.00 ➝ C$6.00
3/12/2021ATB CapitalBoost TargetNAC$1.90 ➝ C$4.20
3/12/2021CIBCBoost TargetNAC$4.25 ➝ C$5.00
3/12/2021Eight CapitalBoost TargetNAC$2.40 ➝ C$3.85
(Data available from 2/2/2021 forward)

News Sentiment Rating

0.20 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 14 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025
  • 0 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/3/2026
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2026

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Organigram logo
Organigram Inc. is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.
Read More

Today's Range

Now: C$2.05
Low: C$2.02
High: C$2.07

50 Day Range

MA: C$2.33
Low: C$2.03
High: C$2.90

52 Week Range

Now: C$2.05
Low: C$1.22
High: C$3.09

Volume

30,783 shs

Average Volume

215,937 shs

Market Capitalization

C$275.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.108093

Frequently Asked Questions

What sell-side analysts currently cover shares of Organigram?

The following Wall Street analysts have issued reports on Organigram in the last year: Canaccord Genuity Group Inc..
View the latest analyst ratings for OGI.

What is the current price target for Organigram?

0 Wall Street analysts have set twelve-month price targets for Organigram in the last year. Their average twelve-month price target is C$3.00, suggesting a possible upside of 46.3%. Canaccord Genuity Group Inc. has the highest price target set, predicting OGI will reach C$3.00 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of C$3.00 for Organigram in the next year.
View the latest price targets for OGI.

What is the current consensus analyst rating for Organigram?

Organigram currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OGI will outperform the market and that investors should add to their positions of Organigram.
View the latest ratings for OGI.

What other companies compete with Organigram?

Other companies that are similar to Organigram include CanniMed Therapeutics, Canopy Growth, Emblem, ICC Labs and Leaf Mobile. Learn More about companies similar to Organigram.

How do I contact Organigram's investor relations team?

Organigram's physical mailing address is 333 Bay Street, Suite 1250, Toronto, ON M5H 2R2, Canada, . The company's listed phone number is 844-644-4726. The official website for Organigram is www.organigram.ca. Learn More about contacing Organigram investor relations.